These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 33368089)

  • 21. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
    Freidel MR; Armen RS
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
    Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
    Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
    Kim SY; Jin W; Sood A; Montgomery DW; Grant OC; Fuster MM; Fu L; Dordick JS; Woods RJ; Zhang F; Linhardt RJ
    Antiviral Res; 2020 Sep; 181():104873. PubMed ID: 32653452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
    Vanderlinden E; Boonen A; Noppen S; Schoofs G; Imbrechts M; Geukens N; Snoeck R; Stevaert A; Naesens L; Andrei G; Schols D
    Antiviral Res; 2023 Sep; 217():105700. PubMed ID: 37562608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
    Gangadevi S; Badavath VN; Thakur A; Yin N; De Jonghe S; Acevedo O; Jochmans D; Leyssen P; Wang K; Neyts J; Yujie T; Blum G
    J Phys Chem Lett; 2021 Feb; 12(7):1793-1802. PubMed ID: 33577324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Pandey AK; Verma S
    Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
    Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.
    Ragotte RJ; Pulido D; Donnellan FR; Hill ML; Gorini G; Davies H; Brun J; McHugh K; King LDW; Skinner K; Miura K; Long CA; Zitzmann N; Draper SJ
    mSphere; 2021 Aug; 6(4):e0064721. PubMed ID: 34378982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses.
    Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A
    Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for Multiple Binding Modes in the Initial Contact Between SARS-CoV-2 Spike S1 Protein and Cell Surface Glycans.
    Parafioriti M; Ni M; Petitou M; Mycroft-West CJ; Rudd TR; Gandhi NS; Ferro V; Turnbull JE; Lima MA; Skidmore MA; Fernig DG; Yates EA; Bisio A; Guerrini M; Elli S
    Chemistry; 2023 Jan; 29(1):e202202599. PubMed ID: 36134621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein.
    Shuster A; Pechalrieu D; Jackson CB; Abegg D; Choe H; Adibekian A
    ACS Chem Biol; 2021 Dec; 16(12):2845-2851. PubMed ID: 34792325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
    Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions*.
    Nie C; Pouyan P; Lauster D; Trimpert J; Kerkhoff Y; Szekeres GP; Wallert M; Block S; Sahoo AK; Dernedde J; Pagel K; Kaufer BB; Netz RR; Ballauff M; Haag R
    Angew Chem Int Ed Engl; 2021 Jul; 60(29):15870-15878. PubMed ID: 33860605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disulfide Bonds Play a Critical Role in the Structure and Function of the Receptor-binding Domain of the SARS-CoV-2 Spike Antigen.
    Grishin AM; Dolgova NV; Landreth S; Fisette O; Pickering IJ; George GN; Falzarano D; Cygler M
    J Mol Biol; 2022 Jan; 434(2):167357. PubMed ID: 34780781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structurally defined heparin octasaccharide domain for binding to SARS-CoV-2 Omicron BA.4/BA.5/BA.5.2 spike protein RBD.
    An Z; Bu C; Shi D; Chen Q; Zhang B; Wang Q; Jin L; Chi L
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129032. PubMed ID: 38159696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
    Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
    ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate.
    Prieto-Fernández E; Egia-Mendikute L; Vila-Vecilla L; Bosch A; Barreira-Manrique A; Lee SY; García-Del Río A; Antoñana-Vildosola A; Jiménez-Lasheras B; Moreno-Cugnon L; Jiménez-Barbero J; Berra E; Ereño-Orbea J; Palazon A
    Emerg Microbes Infect; 2021 Dec; 10(1):1065-1076. PubMed ID: 34013835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.